Urethritis Companies
Companies involved in the healthcare industry, particularly in urology, may play a role in the diagnosis, treatment, or research related to urethritis.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Urethritis Companies Update
November 2023: Roche's new immunoassay, Elecsys® HBeAg quant, can detect the hepatitis B e antigen (HBeAg) in human blood and plasma and provide a quantitative and qualitative reading of its presence, was unveiled on November 2023. With the release of this test, patients will be able to establish the presence or absence of hepatitis B (HBV), the severity of their infection, and the efficacy of their treatment with only one set of laboratory findings and clinical data. In nations that recognize the CE Mark, it is compatible with the cobas® e analyzers. Worldwide, healthcare systems and individuals alike bear the brunt of hepatitis B virus (HBV), the most prevalent form of the virus that affects people of all ages.
the European launch of ResistancePlus® MG FleXible was announced by SpeeDx Pty, Ltd. This test is the first of its kind to identify Mycoplasma genitalium (Mgen), a sexually transmitted infection (STI), as well as indicators linked to azithromycin resistance. With Cepheid's FleXible Cartridge program for the GeneXpert System, this test can only be distributed by Cepheid. Premature birth, infertility, and pelvic inflammatory disease are among reproductive health issues associated with Mgen, which can also cause urethritis, cervicitis, endometritis, and other symptoms.2,3 All Mgen testing guidelines agree that only symptomatic persons should be tested, citing the difficulties of increasing antibiotic resistance and the absence of conclusive evidence that asymptomatic infection causes long-term health consequences.
List of Urethritis Key companies in the market
- F. Hoffmann-La Roche AG
- GlaxoSmithKline
- AbbVie
- Johnson & Johnson
- Merck & Co.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Bayer AG
- AstraZeneca plc
Urethritis Market Highlights:
Urethritis Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
